Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Bu Zhong Yi Qi Tang works by tonifying spleen qi and raising 'sinking' qi according to Traditional Chinese Medicine principles. The formula contains active compounds including astragalosides from Astragalus and ginsenosides from Ginseng, which research suggests have adaptogenic and immunomodulatory properties. These compounds may support energy metabolism and gastrointestinal function. The formula's 'qi lifting' action is traditionally used to address organ prolapse and chronic fatigue by strengthening the body's upward-holding energy. Evidence level: C.
Does Bu Zhong Yi Qi Tang interact with any medications?
Bu Zhong Yi Qi Tang may interact with certain medications due to its herbal components. Ginseng may interact with blood thinners, stimulants, and diabetes medications. Licorice root (containing glycyrrhizin) can potentiate corticosteroids and may affect blood pressure medications. The formula may also enhance effects of other stimulating substances. Patients taking prescription medications should consult a qualified healthcare practitioner before combining with this formula. Evidence level: C.
What is the recommended dosage for Bu Zhong Yi Qi Tang?
The standard adult dosage for Bu Zhong Yi Qi Tang is 4-6 tablets taken three times daily, or as a standard decoction prepared by a qualified herbalist. Dosage may vary based on manufacturer concentration and individual condition. Traditional decoctions are prepared with specific herb ratios. This formula is typically taken long-term for chronic conditions. Always follow practitioner guidance or product labeling for appropriate dosing. Evidence level: Traditional use.
Is Bu Zhong Yi Qi Tang safe during pregnancy?
Bu Zhong Yi Qi Tang is generally considered safe during pregnancy when prescribed by a qualified Traditional Chinese Medicine practitioner. The formula has been used traditionally for pregnancy-related conditions including uterine bleeding and organ support. However, the ginseng component may cause insomnia or overstimulation in some individuals. Pregnant women should always consult their healthcare provider before taking any herbal supplements. Evidence level: C.
What conditions does Bu Zhong Yi Qi Tang treat?
Bu Zhong Yi Qi Tang is traditionally used for conditions associated with spleen qi deficiency and sinking qi. Common indications include chronic fatigue, organ prolapse such as uterine or rectal prolapse, chronic diarrhea, and uterine bleeding. The formula acts as a 'qi lifter' in Traditional Chinese Medicine, helping restore upward-moving energy. It may also support recovery from prolonged illness. Clinical evidence is limited, but the formula has centuries of traditional use. Evidence level: C.
Who should not take Bu Zhong Yi Qi Tang?
Bu Zhong Yi Qi Tang is contraindicated for individuals with acute fever, excess heat conditions, or yin deficiency with fire according to Traditional Chinese Medicine diagnosis. These patterns may be worsened by the warming, tonifying nature of the formula. The ginseng component may cause insomnia or increased heart rate in sensitive individuals. Those with hypertension should use caution due to licorice content. A qualified TCM practitioner should evaluate suitability before use. Evidence level: Traditional.
Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Bu Zhong Yi Qi Tang (BZYQT) is a classical traditional Chinese medicine formula used for over 700 years to treat spleen-qi deficiency and related gastrointestinal and respiratory disorders [PMID:37178982, PMID:36304166].
Contexte
BZYQT is a traditional herbal formulation prevalent in China, Japan, and South Korea [PMID:30981193]. It is composed of ten medicinal plants, including Radix Ginseng (Rensan), Radix Angelicae gigantis (Danggui), Rhizoma Cimicifugae (Shengma), and Radix Bupleuri (Chaihu) [PMID:12067087, PMID:26239548].
Usages traditionnels
It has been traditionally used to treat severe weakness caused by general fatigue, loss of appetite, or indigestion [PMID:28951846], as well as spleen-qi descending, visceroptosis with hyposplenic qi, uterine prolapse, and rectal prolapse due to chronic diarrhea [PMID:24333365].
Composés actifs
Identified bioactive components include astragaloside IV, calycosin, glycyrrhizic acid, enoxolone, saikosaponin D, ferulic acid, and hesperiden [PMID:28113140]. Other major compounds include ginsenoside Rb1 and Rg1, saikosaponin a and c, and glycyrrhizin [PMID:11554610].
Mécanisme d'action
BZYQT exhibits immunomodulatory and anti-inflammatory effects [PMID:30608425]. It has been shown to upregulate TLR4 surface expression in THP-1 cells, potentially enhancing defenses against Gram-negative bacteria [PMID:12040884]. In muscle atrophy models, it modulates atrogenes (atrogin-1 and MuRF1) and AMPK [PMID:36578084]. It also targets monocyte-associated genes in sepsis therapy [PMID:40946819] and induces apoptosis via G0/G1 arrest in hepatoma cell lines [PMID:11554610].
Preuves cliniques
Preuve BCancer-related fatigue
Statistically significant improvements in fatigue levels assessed by VAS-F, FACT-G, FACT-F, and TOI-F [PMID:21059621]
Preuve BPerennial allergic rhinitis
Significant improvement in nasal symptomatic scores compared to a control group [PMID:17980528]
Preuve BPersistent Allergic Rhinitis
High-dose group showed statistically significant improvement in Total Nasal Symptom Score (TNSS) compared to placebo [PMID:38786427]
Preuve ACancer (General)
Promising in alleviating cancer-related symptoms and enhancing anti-cancer effects when combined with conventional treatments [PMID:39300400]
Preuve BIdiopathic male infertility
Administration significantly elevated seminal plasma sFas levels, which correlated with sperm concentration [PMID:14660164]
Sécurité et effets indésirables
High doses may have cytotoxic effects attributed to saponins or detergent-like compounds [PMID:26239548].
Interactions médicamenteuses
BZYQT is one of the most commonly prescribed formulations for cancer patients concurrently with anticancer chemotherapy drugs, though comprehensive evidence for risks and benefits is rare [PMID:29703390]. In rats, it was studied for effects on hepatic drug-metabolizing enzymes and plasma concentrations of tolbutamide [PMID:22564357].
Synthèse des preuves
Evidence ranges from animal models and in vitro studies (D) to randomized clinical trials (B) and scoping reviews (A), showing strong potential for immunomodulation and symptom relief in fatigue and allergic conditions, though more high-level clinical data is needed for many indications.
Sources PubMed
1.PMID: 34421064 (2021) — The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. · Bioscience trends
2.PMID: 40946819 (2026) — Bu Zhong Yi Qi Tang targets key monocyte-associated genes to enhance sepsis therapy. · Journal of ethnopharmacology
3.PMID: 28951846 (2017) — Effects of Bu-Zhong-Yi-Qi-Tang for the treatment of functional dyspepsia: a feasibility study protocol. · Integrative medicine research
4.PMID: 37178982 (2023) — A screening strategy for bioactive components of Bu-Zhong-Yi-Qi-Tang regulating spleen-qi deficiency based on "endobiotics-targets-xenobiotics" association network. · Journal of ethnopharmacology
5.PMID: 12067087 (2002) — The radioprotective effects of bu-zhong-yi-qi-tang: a prescription of traditional Chinese medicine.
Sources gouvernementales
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
6.PMID: 36304166 (2022) — Integrating network pharmacology and experimental verification to decipher the immunomodulatory effect of Bu-Zhong-Yi-Qi-Tang against poly (I:C)-induced pulmonary inflammation. · Frontiers in pharmacology
7.PMID: 39121536 (2024) — Quantitative ternary network-oriented discovery of Q-markers from traditional Chinese medicine prescriptions: Bu-Zhong-Yi-Qi-Tang as a case study. · Phytomedicine : international journal of phytotherapy and phytopharmacology
8.PMID: 30195569 (2019) — Mucosal immunomodulatory evaluation and chemical profile elucidation of a classical traditional Chinese formula, Bu-Zhong-Yi-Qi-Tang. · Journal of ethnopharmacology
9.PMID: 39300400 (2024) — Therapeutic and immunomodulatory effects of Bojungikki-tang on cancer: a scoping review. · BMC cancer
10.PMID: 17980528 (2008) — Antiinflammatory effects of Bu-zhong-yi-qi-tang in patients with perennial allergic rhinitis. · Journal of ethnopharmacology
11.PMID: 30608425 (2019) — The herbal drug, Bu-Zhong-Yi-Qi-Tang, for the treatment of atopic dermatitis: Protocol for a systematic review. · Medicine
12.PMID: 29703390 (2018) — Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. · Journal of food and drug analysis
13.PMID: 24333365 (2014) — Analysis of the restorative effect of Bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model using (1)H-NMR-based metabonomics. · Journal of ethnopharmacology
14.PMID: 26035827 (2015) — Immune-modulatory effects of bu-zhong-yi-qi-tang in ovalbumin-induced murine model of allergic asthma. · PloS one
15.PMID: 30981193 (2019) — In vivo metabolic profiles of Bu-Zhong-Yi-Qi-Tang, a famous traditional Chinese medicine prescription, in rats by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. · Journal of pharmaceutical and biomedical analysis
16.PMID: 37507975 (2023) — A Narrative Review of the Herbal Preparation of Ayurvedic, Traditional Chinese, and Kampō Medicines Applied as Radioprotectors. · Antioxidants (Basel, Switzerland)
17.PMID: 26239548 (2015) — Hochu‑ekki‑to (Bu‑zhong‑yi‑qi‑tang), a herbal medicine, enhances cisplatin‑induced apoptosis in HeLa cells. · Molecular medicine reports
18.PMID: 19360916 (2009) — Effect of Bu-Zhong-Yi-Qi-Tang on deficiency of N-glycan/nitric oxide and islet damage induced by streptozotocin in diabetic rats. · World journal of gastroenterology
19.PMID: 28113140 (2017) — Simultaneous determination of multiple bioactive components of Bu-zhong-yi-qi-tang in rat tissues by LC-MS/MS: Application to a tissue distribution study. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
20.PMID: 22564357 (2012) — Effects of Bu-Zhong-Yi-Qi-Tang on hepatic drug-metabolizing enzymes and plasma tolbutamide concentration in rats. · Journal of ethnopharmacology
21.PMID: 36578084 (2022) — Kampo formula hochu-ekki-to (Bu-Zhong-Yi-Qi-Tang, TJ-41) ameliorates muscle atrophy by modulating atrogenes and AMPK in vivo and in vitro. · BMC complementary medicine and therapies
22.PMID: 14660164 (2004) — Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility. · Archives of andrology
23.PMID: 10794119 (2000) — Anti-aging effects of the traditional Chinese medicine bu-zhong-yi-qi-tang in mice. · The American journal of Chinese medicine
24.PMID: 11554610 (2001) — The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. · Life sciences
25.PMID: 21059621 (2010) — Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. · Integrative cancer therapies
26.PMID: 38786427 (2024) — Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Randomized, Double-Blinded, Placebo-Controlled, Phase II Trial. · Healthcare (Basel, Switzerland)
27.PMID: 25518333 (2014) — [1H NMR based metabolomics study of bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model]. · Yao xue xue bao = Acta pharmaceutica Sinica
28.PMID: 12040884 (2002) — Surface expression of toll-like receptor 4 on THP-1 cells is modulated by Bu-Zhong-Yi-Qi-Tang and Shi-Quan-Da-Bu-Tang. · Methods and findings in experimental and clinical pharmacology